Items where Community is "CSHL labs > Janowitz lab"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Paper
Number of items at this level: 19.

Paper

Janowitz, T. (July 2018) Cancer: The Tumor-Driven Disease of the Host. Cell Metab, 28 (1). pp. 5-6. ISSN 1550-4131

Sng, C. C. T., O'Byrne, S., Prigozhin, D. M., Bauer, M. R., Harvey, J. C., Ruhle, M., Challis, B. G., Lear, S., Roberts, L. D., Workman, S., Janowitz, T., Magiera, L., Doffinger, R., Buckland, M. S., Jodrell, D. J., Semple, R. K., Wilson, T. J., Modis, Y., Thaventhiran, J. E. D. (July 2018) A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. J Allergy Clin Immunol, 142 (1). 311-314.e6. ISSN 0091-6749

Flint, T. R., Jones, J. O., Ferrer, M., Colucci, F., Janowitz, T. (March 2018) A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Semin Oncol. ISSN 0093-7754

Connell, C. M., Raby, S. E. M., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T. (January 2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 23 (1). pp. 116-117. ISSN 1083-7159

Connell, C. M., Raby, S., Beh, I., Flint, T., Williams, E., Fearon, D. T., Jodrell, D. I., Janowitz, T. (July 2017) Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann Oncol, 28 (7). pp. 1678-1679. ISSN 0923-7534

Flint, Thomas R., Fearon, Douglas T., Janowitz, Tobias (May 2017) Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 23 (5). pp. 451-464. ISSN 1471-4914

Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., Fearon, D. T. (November 2016) Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab, 24 (5). pp. 672-684. ISSN 1932-7420 (Electronic)1550-4131 (Linking)

Janowitz, T., Thuss-Patience, P., Marshall, A., Kang, J. H., Connell, C., Cook, N., Dunn, J., Park, S. H., Ford, H. (February 2016) Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer, 114 (4). pp. 381-7. ISSN 0007-0920

Janowitz, T., Welsh, S., Warren, A. Y., Robson, J., Thomas, B., Shaw, A., Ainsworth, N. L., Neal, D. E., Mazhar, D. (October 2015) Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy. BMC Res Notes, 8. p. 524. ISSN 1756-0500

Lu, L., Yan, H., Shyam-Sundar, V., Janowitz, T. (September 2014) Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther, 8. pp. 1539-53. ISSN 1177-8881

Ellul, M., Janowitz, T., Burnet, N. (May 2014) Panhypopituitarism secondary to a solitary hypothalamic metastasis. BMJ Case Rep, 2014. ISSN 1757-790x

Ford, H. E., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., Swinson, D., Falk, S., Chau, I., Cunningham, D., Kareclas, P., Cook, N., Blazeby, J. M., Dunn, J. A. (January 2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol, 15 (1). pp. 78-86. ISSN 1470-2045

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., Fearon, D. T. (December 2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 110 (50). pp. 20212-20217. ISSN 00278424 (ISSN)

Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P., Eisen, T. (August 2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol, 40 (4). pp. 482-91. ISSN 0093-7754

Ubhi, B. K., Cheng, K. K., Dong, J., Janowitz, T., Jodrell, D., Tal-Singer, R., MacNee, W., Lomas, D. A., Riley, J. H., Griffin, J. L., Connor, S. C. (October 2012) Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst, 8 (12). pp. 3125-33. ISSN 1742-2051

Janowitz, T. (January 2011) Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysis. Protein Eng Des Sel, 24 (1-2). pp. 105-11. ISSN 1741-0126

Janowitz, T., Menon, D. K. (April 2010) Exploring new routes for neuroprotective drug development in traumatic brain injury. Sci Transl Med, 2 (27). 27rv1. ISSN 1946-6234

Oliynyk, Z., Briseno-Roa, L., Janowitz, T., Sondergeld, P., Fersht, A. R. (April 2004) Designing a metal-binding site in the scaffold of Escherichia coli KDO8PS. Protein Eng Des Sel, 17 (4). pp. 383-90. ISSN 1741-0126 (Print)1741-0126

Koulen, P., Janowitz, T., Johenning, F. W., Ehrlich, B. E. (October 2001) Characterization of the calcium-release channel/ryanodine receptor from zebrafish skeletal muscle. J Membr Biol, 183 (3). pp. 155-63. ISSN 0022-2631 (Print)0022-2631

This list was generated on Sun Dec 16 12:42:07 2018 EST.
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving